|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:activeIngredient
|
fentanyl
|
|
gptkbp:alternativeTo
|
gptkb:Fentora
Abstral
Lazanda
Subsys
|
|
gptkbp:approvalYear
|
1998
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
N02AB03
|
|
gptkbp:brand
|
gptkb:Teva_Pharmaceuticals
|
|
gptkbp:controlledSubstanceSchedule
|
gptkb:Schedule_II_(US)
|
|
gptkbp:countryOfOperation
|
gptkb:Canada
gptkb:United_Kingdom
gptkb:United_States
|
|
gptkbp:duration
|
1-2 hours
|
|
gptkbp:features
|
keep out of reach of children
not for opioid-naive patients
risk of fatal respiratory depression
|
|
gptkbp:form
|
lozenge
200 mcg
1200 mcg
1600 mcg
400 mcg
600 mcg
800 mcg
|
|
gptkbp:genericName
|
gptkb:fentanyl_citrate
|
|
gptkbp:halfLife
|
3-7 hours
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Actiq
|
|
gptkbp:indication
|
breakthrough cancer pain
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Cephalon
|
|
gptkbp:mechanismOfAction
|
mu-opioid receptor agonist
|
|
gptkbp:onset
|
15-30 minutes
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:prescriptionRestriction
|
REMS program (US)
|
|
gptkbp:riskFactor
|
addiction
abuse
overdose
|
|
gptkbp:routeOfAdministration
|
oral transmucosal
|
|
gptkbp:sideEffect
|
nausea
constipation
drowsiness
respiratory depression
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:bfsParent
|
gptkb:Cephalon
|
|
gptkbp:bfsLayer
|
7
|